Screener
Avalo Therapeutics AVTX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Short-term investments | 314,894 | 82,478 |
| Prepaid expenses and other current assets | 7,607 | 6,913 |
| Restricted cash, current portion | 49 | 37 |
| Total current assets | 407,932 | 105,286 |
| Long-term investments | 71,878 | — |
| Property and equipment, net | 288 | 460 |
| Goodwill | 10,502 | 10,502 |
| Restricted cash, net of current portion | 183 | 210 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's total current assets?
- Avalo Therapeutics (AVTX) reported total current assets of $407.93M in Q2 2026.
- How has Avalo Therapeutics's total current assets changed year-over-year?
- Avalo Therapeutics's total current assets increased by 254.2% year-over-year, from $115.19M to $407.93M.
- What is the long-term trend for Avalo Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Avalo Therapeutics's total current assets has grown at a 32.3% compound annual growth rate (CAGR), from $26.01M to $105.29M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Avalo Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude